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Genome-wide association studies (GWAS) have successfully identiﬁed susceptibility loci from marginal association analysis of SNPs.
Valuable insight into genetic variation underlying complex diseases will likely be gained by considering functionally related sets of genes
simultaneously. One approach is to further develop gene set enrichment analysis methods, which are initiated in gene expression
studies, to account for the distinctive features of GWAS data. These features include the large number of SNPs per gene, the modest
and sparse SNP associations, and the additional information provided by linkage disequilibrium (LD) patterns within genes.We propose
a ‘‘gene set ridge regression in association studies (GRASS)’’ algorithm. GRASS summarizes the genetic structure for each gene as
eigenSNPs and uses a novel form of regularized regression technique, termed group ridge regression, to select representative eigenSNPs
for each gene and assess their joint association with disease risk. Compared with existing methods, the proposed algorithm greatly
reduces the high dimensionality of GWAS data while still accounting for multiple hits and/or LD in the same gene. We show by simu-
lation that this algorithmperformswell in situations inwhich there are a large number of predictors compared to sample size.We applied
the GRASS algorithm to a genome-wide association study of colon cancer and identiﬁed nicotinate and nicotinamide metabolism and
transforming growth factor beta signaling as the top two signiﬁcantly enriched pathways. Elucidating the role of variation in these
pathways may enhance our understanding of colon cancer etiology.Introduction
The complete sequence of the human genome, the
HapMap Project, and recent advances in genotyping tech-
nology have made large-scale genome-wide association
studies (GWAS) feasible. As a result, many novel suscepti-
bility loci have been identiﬁed from the marginal associa-
tion analysis of SNPs with disease risk.1 However, there is
far more information in the data that researchers are just
beginning to explore. One particular topic of interest is
how germline variation from genes with related functions
may affect disease risk.
It is well established that functionally related genes can
act concordantly2 and that their action may be inﬂuenced
by genetic variation in the chromosomal region of the
gene (including the coding region, as well as the upstream
and downstream sequences). The dense SNPmarker panels
from GWAS offer an unprecedented opportunity to com-
prehensively study germline variability of gene sets.
Several informatics databases, such as the gene ontology
(GO) database,3 the Kyoto Encyclopedia of Genes and
Genomes (KEGG),4 and the Molecular Signatures Database
(MSigDB),5 have been curated to provide information on
functions and relatedness of genes and to classify genes
into gene sets with common underlying features. By as-
signing SNPs to the nearest genes based on genomic loca-
tion, one can combine information on all of the variation
in the same gene set and collectively assess the association
with disease risk. Such analysis can provide valuable1Biostatistics and Biomathematics Program, Public Health Sciences Division,
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Indeed, the successes of using prior knowledge to assess
gene set association in GWAS have been reported in stud-
ies of diseases including Parkinson disease,6,7 age-related
macular degeneration,7 multiple sclerosis,8 and bipolar
disorder.9
Gene set enrichment analysis was ﬁrst proposed by
Mootha et al.10 for detecting concerted changes in the
expression of genes groupedby their functional relatedness.
It has shown great promise in deriving new information
fromexpressiondata.Manymethodshave since beendevel-
oped; see, for example,Goemanet al.,11 Subramanianet al.,5
Tianet al.,12 EfronandTibshirani,13 JiangandGentleman,14
and Dinu et al..15 Two recent papers16,17 provide a compre-
hensive review and comparison of these various methods.
Two different approaches are usually taken in assessing
gene set enrichment for expression data. The ﬁrst approach
investigates whether a gene set of interest is enriched with
genes differentially expressed between two biological states
in comparison to a random gene set. To generate the null
distribution for this approach, one can randomly sample
genes from the same data set to form random gene sets
and calculate null statistics for these random gene sets.
The second approach tests the null hypothesis that the
gene set of interest does not contain any gene or genes
differentially expressed between two biological states.
For this approach, one could permute phenotype labeling
in the data and calculate null statistics based on the per-
muted phenotypes. In either approach, one can obtainFred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA;
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nonparametric p values of gene set association by com-
paring the observed statistics with the null statistics
obtained under the respective null hypothesis.
Compared to expression data, there are several distinc-
tive features in genome-wide association data that require
different methodological consideration. First, in contrast
to gene expression data, in which each gene contains
only a few transcripts, in GWAS data, each gene is
comprised of a relatively large number of SNPs because of
the high density of marker panels. Second, in contrast to
gene expression data, in which many genes are up- or
downregulated in the diseased group versus the nondi-
seased group, the SNP associations in GWAS data tend to
be modest and somewhat sparse. Third, many SNPs are
in linkage disequilibrium (LD), and using information
from these SNPs jointly can enhance the power for detect-
ing disease risk variants, including detecting variants that
are not directly genotyped.
Methods for gene set enrichment analysis have been
developed for GWAS data. For example, Wang et al.7
extended the method developed by Subramanian et al.5
to GWAS data. PLINK,18 a popular software for analyzing
GWAS data, offers an option to perform gene set analysis,
which we will shorthand by Plink. Holmans et al.9
proposed an approach called ALIGATOR (association list
go annotator), which does not require individual-level
SNP data. Generally speaking, all of these methods are
based on marginal association analysis of each SNP and
don’t make use of LD structure in the data. As such, ungen-
otyped disease-associated variants may not be best ac-
counted for in the gene set analysis. Plink formulates
gene set statistics on the basis of SNPs, whereas Wang
et al.’s method and ALIGATOR are based on genes. Wang
et al. chooses the most signiﬁcant associated SNP in each
gene, and ALIGATOR chooses the genes that are hit by
any of the top SNPs. Because the number of SNPs in a
gene can be large, test statistics based on genes that are rep-
resented by only one SNP may lose power after adjusting
for the gene size. They may also lose power because of
not accounting for the potential multiple hits in a gene.
Further discussion about these methods and the compar-
ison with the proposed method is given in the Results.
In this paper, we present a gene set association method
that accounts for each of these distinctive properties of
GWAS data. We ﬁrst assign SNPs to genes and summarize
the variation of a gene by principal components,19 which
we term as ‘‘eigenSNPs.’’ The eigenSNPs capture the overall
gene structure and reduce the local correlation because of
linkage disequilibrium.We then propose to use regularized
regression technique20 to select one or more representative
eigenSNPs for each gene and assess their joint association
with disease risk. The regularization is necessary because
the total number of predictors, here eigenSNPs, is quite
large compared to the sample size. We propose an algo-
rithm called ‘‘gene set ridge regression in association
studies (GRASS),’’ which performs regularized logistic
regression and assesses the gene set association. The under-The Amelying framework in the GRASS algorithm is regression
based and therefore can be readily extended to incorporate
covariates and to include gene-gene and gene-environ-
ment interaction effects at the SNP level.Materials and Methods
Capturing Gene Structure with Principal
Component Analysis
The ﬁrst step of our method is to summarize the genetic variation
in each gene. This is performed prior to our gene-set-based anal-
ysis. Often, SNPs within the same gene are in LD and may repre-
sent redundant information. Furthermore, genotyped SNPs may
tag the true risk-associated variants, which may or may not have
been genotyped. It is therefore desirable to capture the unique
genetic variation within a gene to reduce the dimensionality of a
gene and tag the ungenotyped potential risk variants. In addition,
because our gene set analysis is regression based, constructing
unique (orthogonal) components will also enhance both the inter-
pretability of selected components and the chance of identifying
components that are most strongly associated with disease risk.21
For each gene, we use principal components analysis (PCA) to
decompose the genetic variation into orthogonal components.
We perform PCA as follows: let n be sample size and m be the
number of SNPs in a gene. We ﬁrst standardize the m 3 n SNP
matrix for each gene, as proposed in Price et al.,22 so that SNPs
with different minor allele frequencies (MAFs) are weighted
equally. We apply singular value decomposition on the standard-
ized SNP matrix, Z, and obtain Z ¼ UDV0. Essentially, the decom-
position projects the complete data onto a reduced eigenspace V
of dimension l (l%m). Thematrix U is anm3 l orthogonal matrix
with columns corresponding to sample SNP variations, and the
matrix V is an n 3 l column orthogonal matrix, each column of
which is deﬁned as an eigenSNP and is a linear combination of
all the relevant real SNPs. The matrix D is a diagonal matrix in
which the jth diagonal entry dj is the eigenvalue of the jth
eigenSNP. EigenSNPs are decreasingly ordered by jdjj, and
pj ¼ d2j =
P
j0 d
2
j0 represents the proportion of variation in the gene
accounted for by the jth eigenSNP. Because a gene contains m
SNPs, each with unit variance, if the proportion of variation of
an eigenSNP i captured is equal to or greater than 1/m, i.e., pi R
1/m, we call the eigenSNP a nontrivial eigenSNP. For each gene,
we select all the nontrivial eigenSNPs, which altogether explain
~95% of the gene variation. When applying group ridge regres-
sion, the nontrivial eigenSNPs from all the genes in the same set
will be treated as predictors in the regression.Group Ridge Regression with Lasso Penalty
within the Group
The essence of the proposed GRASS algorithm is to identify associ-
ation signals based on predeﬁned gene sets via regularized regres-
sion. The intuition behind regularized regression is as follows:
ordinary maximum likelihood estimation is sometimes not
achievable or not efﬁcient, particularly when the sample size is
small relative to the number of predictors. In such cases, we can
choose to trade bias for efﬁciency in estimation by maximizing
the log likelihood function, subject to some constraint, or equiva-
lently by minimizing the negated log likelihood plus the penalty
function, which has a one-to-one relationship with the constraint.
Many penalty functions have been proposed for regularizingrican Journal of Human Genetics 86, 860–871, June 11, 2010 861
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Properties of Different Penalty Functions
A graphic illustration of the properties of
three different penalty functions. The
eclipses represent the likelihood contours.
(A–C) The square, round, and star shapes
represent the lasso, ridge, and bridge
constraint, respectively. The dots are the
points where likelihood contours are ‘‘tan-
gent’’ to the constraints, i.e., the penalized
likelihood estimates. Note that in lasso (A)
or bridge (C), the constraint is discontin-
uous at zero. If the likelihood contour ﬁrst
touches the constraint at point zero, the
corresponding parameter estimate is zero,
and variable selection is achieved.parameter values bi for i ¼ 1, ., p predictors. For example, the
lasso penalty20 is the [1 norm of parameter values, in which the
[g norm of parameter vector b is deﬁned as kbkg ¼ ð
Pp
i¼1jbijgÞ
1
g,
g > 0. Therefore, the lasso penalty function is deﬁned as
kbk1 ¼
Pp
i¼1jbij. The ridge23 and bridge penalty24 take the form
of the [2 and [g norm with 0 < g < 1, respectively. As expected,
different penalty functions affect the estimation in different
ways. Figure 1 shows the behavior of these three penalty functions
in a two-parameter case, b1 and b2. To obtain maximum con-
strained likelihood estimators, we essentially seek the points at
which the log likelihood contour ﬁrst ‘‘hits’’ the constraint. Lasso,
ridge, and bridge penalty functions have constraints shaped like
a square, circle, and star, respectively. As a consequence of the
different shapes, lasso is likely to involve variable selection (b1 ¼ 0
or b2¼ 0), as well as parameter estimate shrinkage, and ridge yields
mainly parameter estimate shrinkage; in contrast, bridge induces
an even higher chance of variable selection than lasso, because
the star shape of bridge makes the likelihood contour even more
likely to hit one of the points (b1 ¼ 0 or b2 ¼ 0) than does the dia-
mond shape of lasso.25
For gene set association analysis, we would like the estimation to
capture the effects of all genes in the same pathway by using the
most representative eigenSNPs in each gene. Note, in this context,
that ‘‘the most representative eigenSNPs’’ refers to those that are
most associated with disease risk. They are not necessarily the
eigenSNPs that explain the most variation in a gene. This requires
variable selection within a gene while shrinking the parameter
estimates for the gene effects across genes. Clearly, none of the
penalty functions discussed above meet these objectives. We
therefore propose a group ridge penalty that is speciﬁcally tailored
to the gene set association analysis via GWAS data. The group ridge
combines [2-norm regularization at the gene level and [1-norm
regularization within each gene. It shrinks (by ridge) the con-
tribution to disease risk from each gene to down-weigh genes
that may otherwise possibly exhibit extreme associations because
of stochastic variation while performing eigenSNP variable selec-
tion (by lasso) within each gene simultaneously. This penalty
function ensures that each gene contributes to the association
score of the gene set. The amount of the contribution from each
gene is determined ﬂexibly by selecting the most associated
eigenSNPs, which could be more than one, within the gene.
In comparison, a simple lasso penalty would primarily impose
variable selection among all eigenSNPs, regardless of which gene
they belong to. This may result in gene set statistics being domi-
nated by a single eigenSNP or by eigenSNPs from only a few genes.
This somewhat contradicts the essence of the gene set association862 The American Journal of Human Genetics 86, 860–871, June 11,analysis, in which interest is on the assessment of the collective
effect of a gene set on disease risk. Two other possible group-based
penalty functions have also been proposed in the literature: group
lasso26 and group bridge.27 In our context, group lasso does
considerable variable selection at the gene level while retaining
all eigenSNPs in the selected genes. As such, it also deviates from
the motivation of gene set association analysis. Group bridge does
considerable variable selection at both the gene and eigenSNP
levels and can therefore be overly selective and miss useful, albeit
modest, association signals in GWAS data.
LetX¼ {V1,.,VG} be an n3 p pooled eigenSNPmatrix of a gene
set S with G total genes, in which Vg(g ¼ 1, ., G) is an n 3 kg
eigenSNP matrix for gth gene and n, kg, and p ¼
PG
g¼1
kg are the
number of samples, the number of eigenSNPs in the gth gene,
and the total number of eigenSNPs in the gene set, respectively.
Let the parameter vector be denoted by b ¼ ðb0,bT1 ,.,bTGÞT, in
which b0 is the intercept and bg(g ¼ 1,., G) is the vector of cor-
responding regression coefﬁcients for Vg. To simplify the represen-
tation of the log likelihood, we recode the disease status y ¼ 1 for
diseased and –1 for nondiseased. The log likelihood function can
then be written as
[ðbÞ ¼ 
Xn
i¼1
ln

1þ expXib,yi: (Equation 1)
The group ridge (GRASS) estimator, bbl, can be obtained by mini-
mizing the penalized likelihood function, which is the negated log
likelihood plus the penalty term, given by
SlðbÞ ¼ [ðbÞ þ l
XG
g¼1
wg
kbgk12, (Equation 2)
in which kbgk1 ¼
P
j˛geneg
jbjj, and l is a penalty parameter that
governs how much penalty will be imposed on the parameter
estimators. As one can see, the penalty function is the sum of
squares of the [1 norm kbgk1 over all genes weighted by a weight
functionwg. It applies the ridge penalty among genes and the lasso
penalty within each gene. Note that the intercept is not ‘‘regular-
ized.’’
Different weighting options,wg, for the penalty term can impact
the estimation. One can weigh each gene equally by using wg ¼ 1.
Alternatively, one can assign weights based on gene length. For
example, genes with more eigenSNPs may be penalized more by
employing a weight, wg ¼
ﬃﬃﬃﬃﬃ
kg
p
, suggested by Yuan and Lin.26
This weight function rescales the penalty function with respect
to the dimensionality (number of eigenSNPs) of the parameter2010
vector, bg. In our analysis, we choose wg ¼ 1, so that genes with
different numbers of eigenSNPs are evaluated equally in the set.
However, to ensure that each gene contributes equally, we stan-
dardize the statistic contributed by each gene when forming the
gene set statistics (see below).
Group Ridge Estimation Algorithm
Weminimize the function in Equation 2 to obtain the group ridge
estimator, bbl. When the number of genes and eigenSNPs is large,
minimizing SlðbÞ can be challenging. Our GRASS algorithm
adopts ideas from several algorithms in the literature.28–30 We
use a block coordinate descent method to search for the optimal
estimate for each block (group and gene), and, within each
block, we employ a cyclic coordinate descent algorithm28,29 (see
Appendix A, Algorithm A1 for the general idea, and Algorithm
S1 and S2 available online for detailed procedures).
Brieﬂy, the algorithm decreases the objective function one coor-
dinate (parameter) at a time while ﬁxing other parameters at the
current values. The procedure is repeated until some convergence
criterion is met. To ﬁnd the tentative next step, we use a one-step
Newton-Raphson algorithm. The Newton-Raphson algorithm
requires the objective function to be convex and smooth in order
to ﬁnd the minimum. With the group ridge penalty, the objective
function is convex and smooth everywhere except for when some
component of the regression vector equals zero as a result of the
lasso penalty within a gene. Therefore, at each tentative step,
the algorithm checks whether the estimate crosses zero and, if
so, the estimate is set to zero. When the current estimate is zero,
the algorithm tries both directions to see whether either direction
improves the objective function and, if not, then the estimate
remains zero. Because of convexity, it is not possible for both direc-
tions to improve the objective function.
We choose l by Akaike’s information criterion (AIC) for each
gene set. AIC is deﬁned as AIC ¼ 2p – 2[, in which p is the number
of parameters in the model and [ is the log likelihood for the
estimated model.31
Gene Set Association Analysis
After l is chosen based on AIC, we obtain the regression estimates
at the optimal l value and use these estimates to measure the
strength of the association of the gene set with disease risk.We ﬁrst
summarize the association of each gene and then summarize the
association of all genes together. By doing this, we can avoid
potential bias as a result of varying gene size. Speciﬁcally, the
gene-level association is estimated by
kbblgk ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃbb2g1 þ bb2g2 þ.þ bb2gkg
r
, (Equation 3)
where bbg1,.,bbgkg are the estimated regularized log odds ratios for
eigenSNPs in the gene g, obtained from minimizing SlðbÞ with
the optimal l value. Note that because of the variable selection
feature of group ridge within each gene, many of the estimated
regularized log odds ratios are zero.
To adjust for gene size, one can choose a weighting function wg
in Equation 2 based on the structure of the data; however, the
choice can be ad hoc. Here we use a permutation-based approach
to adjust for gene size. Speciﬁcally, we use wg ¼ 1 in Equation 2 to
obtain bblg and to standardize the gene-level statistic, kbblgk, by
~bg ¼
kbblgk  bmgbsg , (Equation 4)The Amein which bmg and bsg are the mean and standard deviation estimates
of kblgk under the null hypothesis that the gene g is not associated
with disease risk. In this way, every gene, regardless of its size,
contributes equally to the gene set association statistics. To esti-
mate bmg and bsg , we permute the case and control status B times,
and for each permutation we obtain kbb0lgk via the same l value
as the original data set. We then calculate bmg and bsg by the
mean and standard deviation of kbb0lgk s over B permutations.
The gene set association statistic for a gene set S is then
deﬁned as
Tl ¼ k~bk ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
~b
2
1 þ.þ ~b
2
G
q
, (Equation 5)
in which ~bg ,g ¼ 1,.,G are the standardized estimates (Equation 4)
for each gene g in the set. Via the same permutation, we can stan-
dardize the gene set statistics under the null hypothesis and obtain
the B null statistics T0b(l), b ¼ 1, 2,., B.
To test whether the gene set S is associated with disease risk, we
compare the observed statistic Tlwith the null statistics and calcu-
late the p value as
p value ¼

T0b ðlÞRTl; b ¼ 1,2,.,B

B
: (Equation 6)
Another option is to approximate the p value based on a normal
distribution for Tl under the null hypothesis by 1F1 TlmGðlÞsdGðlÞ

.
One could estimate the mean, mG(l), and standard deviation,
sdG(l), of Tl under the null hypothesis based on fewer number
of permutations than that for nonparametric p values in Equation
6 and thus save on computation time substantially.We summarize
GRASS in Algorithm A2 in the Appendix.Results
Simulations
Comparison with Other Penalty Functions
We simulated different scenarios to evaluate the perfor-
mance of group ridge logistic regression under the null
and alternative hypotheses. In each simulation set, we
compared the proposed group ridge penalty with several
commonly used penalties: lasso,20 group lasso,26,30 group
bridge,27 and conventional logistic regression with no
penalty. The lasso penalty is the [1 norm of parameter
values
Pp
i¼1jbij, in which p is the total number of predictors
in the regression. The group lasso penalty uses [1 norm at
the group level and [2 norm within each group, and it is
deﬁned as
PG
g¼1kbgk2, in which G is the number of groups.
The group bridge penalty uses [g norm (0 < g < 1) at the
group level and [1 norm within each group. Here we chose
g ¼ 0.5, and the group bridge penalty is then deﬁned
as
PG
g¼1ðkbgk1Þ0:5.
For group ridge, lasso, group lasso, and group bridge
penalty functions, we estimated the bs by minimizing
the negated log likelihood plus the corresponding term
deﬁned by different penalty functions, similar to Equation
2. We chose the penalty parameter l for each simulated
gene set by AIC criterion. For no penalty, we obtained
the b estimates by applying univariate logistic regressionrican Journal of Human Genetics 86, 860–871, June 11, 2010 863
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Figure 2. p Values under the Null for Different Penalty Functions with Fixed and Selected l
(A and B) p value histograms from different penalty functions under the null, with penalty parameter value for null statistics chosen by
AIC for each permuted data set (A) and penalty parameter value ﬁxed by the value of l in the corresponding original pathway (B).on each of the simulated eigenSNPs. To calculate the
p values for each penalty function, we used the permuting
phenotype scheme proposed above. We then summarized
and standardized gene level statistics according to Equa-
tion 4 and formulated the gene set level statistics with
Equation 5. To save computation time, we used B ¼ 100
permutations to evaluate the general trend of the perfor-
mance for each method (we used B ¼ 1000 in the real
data analysis described below to increase accuracy). For
each permutation, we ﬁxed the penalty parameter value
to the corresponding l used in calculating the observed
statistic for the gene set being tested. We also performed
a set of simulations, in whichwe chose the optimal penalty
parameter value by AIC for each permuted data set, and
found that the two choices were generally comparable
(see Figure 2). Because ﬁxing l saves substantial computing
time, we performed the rest of the simulation study with
ﬁxed l.
In all of the simulations, we simulated 500 cases and 500
controls. For each set of simulations, we generated 100
pathways, with 20 genes each. For each gene, we generated
a group of eigenSNPs in which each eigenSNP is normally
distributed with effect size being zero under the null (simu-
lation A) andmoderate additive effect size, (0.20, 0.12, and
0.10 for simulations B, C, and D, respectively). In simula-
tions B, C, and D, the alternative gene sets consist of 1,
5, and 10 genes, respectively, each harboring one eigenSNP
associated with disease risk. Thus, the three alternative
simulations have decreasing effect sizes but with increas-
ing amount of signals. In simulations A1, B1, C1, and
D1, each gene has k eigenSNPs, in which k is randomly
selected from 3 to 20. Thus, the total number of eigenSNPs,
p, in a pathway is ~200, which is less than the sample size,
N ¼ 1000. In A2, B2, C2, and D2, we increase the
maximum of gene size from 20 to 100 eigenSNPs and
generate k randomly from 3 to 100, so that pR N.
Figure 2 shows the p value histograms under the null
hypothesis for different penalty functions when p < N,
with varying gene size (each gene harbors 3–20864 The American Journal of Human Genetics 86, 860–871, June 11,eigenSNPs) based on 1000 simulations. The histograms
show that group ridge gives a nearly uniform distribution.
An advantage of p values being uniformly distributed is
that we can accurately estimate false discovery rates
(FDR) when accounting for multiple hypothesis testing.
In comparison, the distributions for lasso, group lasso
and group bridge are more like a mixture of a continuous
distribution and a point mass at 1. This is because these
penalty functions do considerable variable selection, and
for many null pathways they don’t select any genes. For
these cases, the test statistics would be 0, which yields
p ¼ 1. We also observed a slightly inﬂated type I error
rate under the null, especially for lasso penalty when
p R N (see Table 1, simulations A1 and A2). When we
set all gene sizes equal or increased the number of permu-
tations to B R 1000, all of the methods controlled the
type I error rate. This suggests that when adjusting for
gene size in the test statistics, the standard deviations in
Equation 4 are not well estimated, particularly if it is
a mixture distribution of lasso type of statistics. Therefore,
for lasso penalty when adjusting for gene size, a larger
number of permutations is required to better control the
type I error rate.
In Table 1, when both p<N and pRN, group ridge is the
most powerful among all of themethods, with lasso closely
behind. Group lasso deviates from the goal of pathway
analysis and does not behave well in any situation. The
no-penalty and groupbridge approaches have intermediate
performances. Lasso penalty often yields a smaller number
of selected variables than group ridge and tends to favor
pathways with a single SNP, having a large effect. Group
bridge penalty selects even fewer variables than lasso and
incurs a substantial loss of power. For the no-penalty
approach, the performance deteriorates as the signal-to-
noise ratio decreases. This is probably because the no-
penalty approach, which is really just the ordinary logistic
regression, includes many nonassociated SNPs in the test
statistic and thus has reduced power to detect disease risk-
associated gene sets when the signal is low.2010
Table 1. Type I Error Rates and Power for Different Penalty Functions
Set N1 p2 G*/G3 Effect Size
Type I Error or Power (a ¼ 0.05)
Group Ridge (GRASS) Lasso No Penalty Group Lasso Group Bridge
A1 1000 ~200 0/20 0 0.06 0.07 0.07 0.01 0.06
A2 1000 ~1000 0/20 0 0.07 0.09 0.08 0.06 0.04
B1 1000 ~200 1/20 0.2 0.73 0.69 0.29 0.24 0.22
B2 1000 ~1000 1/20 0.2 0.61 0.55 0.18 0.08 0.11
C1 1000 ~200 5/20 0.12 0.72 0.66 0.37 0.19 0.22
C2 1000 ~1000 5/20 0.12 0.51 0.43 0.14 0.06 0.12
D1 1000 ~200 10/20 0.1 0.80 0.76 0.54 0.09 0.53
D2 1000 ~1000 10/20 0.1 0.51 0.45 0.18 0.09 0.13
Summary of type I error rates (set A) and power (sets B, C, and D) for group ridge, lasso, no penalty, group lasso, and group bridge under various simulation
scenarios. The significance level a ¼ 0.05.
1 Sample size.
2 Total number of eigenSNPs in each pathway.
3 Number of genes associated with disease risk (numerator) out of the total number of genes (denominator) in each set.In summary, group ridge appears to have uniformly
distributed p values under the null. The uniform distribu-
tion doesn’t seem to change whether we ﬁx or optimize
l in the null statistic calculation and thus can be imple-
mented with ﬁxed l to increase computational efﬁciency.
It provides good power when the number of signals is rela-
tively small, and the effect size is moderate even in the
‘‘large p small n’’ situation. We have also examined the
approximate p values based on the asymptotic normal
distribution with a moderate number of permutations
(B ¼ 100). The performance is comparable with nonpara-
metric p values, though with much less computation
time. However, the asymptotic theory of group ridge has
not yet been established. Hence, in applications in which
the test statistics may not follow a normal distribution, it
would be prudent to use nonparametric p values.
Comparison with Other Gene-Set-Based Approaches
We also simulated different scenarios to compare the
proposed GRASS algorithm with recently published gene-
set-based approaches. These include the method by Wang
et al.,7 the PLINK gene set option,18 and ALIGATOR byHol-
mans et al.9 Brieﬂy, the idea behind the method by Wang
et al. is to assign the top individual SNP association statistic
within thegeneas the statistic of thegeneand to rank all the
genes by signiﬁcance. The method then compares the
distribution of the ranks of genes from a given pathway to
that of the remaining genes via a weighted Kolmogorov-
Smirnov test, with greater weight given to genes with
more extreme statistic values. PLINK18 offers an option to
perform gene set analysis (we termed this ‘‘Plink’’). For
each pathway, Plink selects up to Nsnp ‘‘independent’’
SNPs (here independent is deﬁned as the pair-wise r2s all
below a certain threshold) with marginal association p
values less than a predetermined threshold. The method
calculates the pathway statistic as the average of the test
statistics from the selected SNPs. The signiﬁcance levelsThe Amefor pathways are determinedbypermuting thephenotypes,
and it compares the observed pathway statistics to the null
statistics calculated from permutation. ALIGATOR9 is
similar to Plink in the sense that both use a preselected p
value threshold to deﬁne a set of signiﬁcantly associated
SNPs. Plink averages the test statistics over all of these
SNPs, whereas ALIGATOR counts the number of genes in
a pathway that contains these SNPs, with each gene
counted only once regardless of the number of signiﬁcant
SNPs in the gene. Instead of permuting phenotypes to
establish the null distribution as in Plink, ALIGATOR uses
resampling of SNPs. ALIGATOR thus only requires a p value
or summary statistic from each SNP as input.
Our simulation is based on real colon cancer GWAS data
from theWomen’s Health Initiative (WHI) study.32 A more
detailed description of the data set can be found in the
next section. We chose a random KEGG pathway with
20 genes, the HSA00534 heparan sulfate biosynthesis
pathway, as our basic pathway to simulate different sce-
narios. Different methods have slightly different ways of
deﬁning a gene region and assigning SNPs to genes. In
this simulation, we adopted the deﬁnition of a gene region
suggested by Holmans et al.9 to make the SNP assignments
consistent for all methods: SNPs that are within 20 kb of
the exons of a gene are assigned to the gene. In simulation
E1, we chose the ﬁve smallest genes (ranging from 4 to 11
SNPs) from this pathway, and for each gene we randomly
selected one SNP (we call it the ‘‘tagging’’ SNP) and simu-
lated one causal SNP, which is in LD, with the tagging
SNP (maximum r2 ¼ 0.8). We then simulated the case-
control status based on the model logit PrðY ¼ 1Þ ¼gfP5
i¼1biSNPi þ 3, in which SNPis are the simulated causal
SNPs with the log odds ratios bis generated from U[1.3,
1.4] and 3 follows a standard normal distribution. These
simulated casual SNPs are not included in the SNP data,rican Journal of Human Genetics 86, 860–871, June 11, 2010 865
Table 2. Power Comparison with Existing Pathway Approaches
Set G1 p2 Causal SNPs a Level
Power
Wang Plink ALIGATOR GRASS
E1 20 444 53 0.05 0.48 0.68 0.41 0.87
0.01 0.24 0.35 0.24 0.79
E2 20 444 54 0.05 0.54 0.92 0.55 0.91
0.01 0.18 0.50 0.16 0.80
F1 30 2286 same as in E1 0.05 0.29 0.44 0.18 0.87
0.01 0.20 0.23 0.02 0.80
F2 30 2286 same as in E2 0.05 0.32 0.80 0.33 0.87
0.01 0.17 0.61 0.13 0.73
Summary of power comparison of Wang et al.,7 Plink,18 ALIGATOR,9 and the proposed GRASS under various simulated scenarios.
1 Number of genes.
2 Total number of SNPs.
3 One causal SNP in each of the five smallest genes (range: 4–11 SNPs).
4 One causal SNP in each of the five largest genes (range: 28–91 SNPs).nor are they in the subsequent gene set analysis. However,
the tagging SNPs are kept. For genes in which SNPs are in
LD, many of them may be associated with disease risk.
With this simulation, we kept the real LD structures in
the data and the potential moderate correlation structures
of a real biological pathway. In simulation E2, we chose the
ﬁve largest genes (ranging from 28 to 91 SNPs) to embed
the causal loci and simulated the disease status, similar to
E1. Note that here the deﬁnition of large versus small genes
is deﬁned by the number of SNPs in the gene. Therefore,
a larger gene likely has more SNPs in LD with the causal
locus than a smaller gene. In simulations F1 and F2, we
kept the same structures as in E1 and E2, respectively, but
modiﬁed the pathway size by adding ten random very
large genes with 105–290 SNPs to the pathway. The total
number of SNPs in the pathway HAS00534 heparan sulfate
biosynthesis is 444 (in E1 and E2), and with the ten added
genes, the total number of SNPs in the pathway is 2286
(in F1 and F2). These simulations represent four different
scenarios: in E1, the signals reside in small genes with
few SNPs in LD, whereas in E2, the signals are in larger
genes with more SNPs in LD. In simulations F1 and F2,
both the number of nonassociated genes and the number
of nonassociated SNPs are increased. This will reduce the
signal-to-noise ratio in F1 and F2. For each simulation
scenario, we generated 100 data sets. We want to point
out that we didn’t simulate scenarios with which the
pathway has only one signiﬁcantly associated SNP in one
gene, because we think such signals would likely be picked
up by marginal association analysis and do not need
pathway analysis for detection.
We evaluate the performance of Wang et al., Plink,
ALIGATOR, and our proposed GRASS algorithm. For Plink
and ALIGATOR, p < 0.01 was used to deﬁne the signiﬁ-
cance of the SNPs. For Plink, SNPs with LD r2 > 0.5 are
ﬁltered out. All methods control the type I error rate866 The American Journal of Human Genetics 86, 860–871, June 11,(data not shown). Because of the discrete nature of the
test statistic of ALIGATOR, which is deﬁned as the number
of genes ‘‘hit’’ by signiﬁcant SNPs, ALIGATOR can be
conservative when the number of genes in a pathway is
small or when SNP signiﬁcance threshold is set to be high.
Table 2 shows the power comparison of these methods
in the four simulated scenarios. It can be seen that for
signals residing in small genes (simulations E1 and F1),
GRASS is more powerful than all other methods. For
signals residing in large genes, Plink and GRASS have com-
parable power when a < 0.05, and both perform better
than the Wang et al. method and ALIGATOR. When
we choose a more stringent signiﬁcant cutoff, a < 0.01,
the power of GRASS is much higher than all other
methods. As the number of nonassociated genes increases
(in F1 and F2), all methods lose power, with GRASS losing
the least. This is because GRASS selects disease-associated
eigenSNPs within a gene while shrinking the contributions
of genes to the pathway statistic. So when there are more
nonassociated genes added to the pathway, GRASS will
shrink the contributions of these genes to a small amount
compared to those associated with disease risk, regardless
of the number of SNPs in the gene. Thus, those large and
nonassociated genes did not hurt as much to the power
of the GRASS method as to other approaches.
It is interesting to see that Plink has good power when
the signals reside in large genes. This is probably because
in large genes, more SNPs are in LD with the causal locus
than in small genes, which makes Plink less likely to miss
the region that harbors the causal locus. Another possible
reason may be that even though Plink ﬁlters out SNPs in
high LD (here r2 > 0.5), the remaining selected SNPs are
not absolutely ‘‘independent’’; there might still be small
to moderate LDs among the selected SNPs. Because Plink
pathway statistic is deﬁned as the average statistic of all
the selected SNPs, the small to moderate LDs among those2010
Table 3. Top-Ranking KEGG Pathways Associated with Colon Cancer Risk in the Women’s Health Initiative Sample
Rank KEGG Number Pathway Name No. Genes/No. eigenSNPs p Value
1 HSA00760 Nicotinate and nicotinamide metabolism 23/602 0.015
2 HSA04350 TGF-beta signaling 89/2912 0.035
Top-ranking KEGG pathways that are associated with colon cancer risk at significance level a ¼ 0.05. p values are calculated from Equation 6 based on 1000
permutations.SNPs, particularly if they are also in LDwith the causal SNP,
may help boost the power.
The powers of Wang et al. and ALIGATOR are compa-
rable, regardless of whether the signals are in small genes
or in large genes. This is because the gene set statistics for
both methods use essentially only the strongest signal
within each gene. Wang et al. chooses one SNP within
each gene that has the maximum association test statistic.
ALIGATOR counts a gene only once, even if there are
multiple SNPs in the gene passing the p value threshold.
Neither method makes use of the LD information, and as
a result, they may lose power compared to other methods
in situations. For example, multiple SNPs in a gene are in
LD with the causal SNP or multiple independent causal
SNPs associated with disease risk in a gene, although we
didn’t simulate the latter case. In contrast, GRASS is more
ﬂexible in terms of number of SNPs (or eigenSNPs) being
selected in a gene, and thus it is less likely to miss these
multiple disease-associated SNPs in the gene. Plink’s test
statistic is based on SNPs, not on genes, and therefore is
also able to account for multiple associated SNPs in a single
gene.
A Colon Cancer Genome-wide Association Study
We applied the GRASS algorithm to a colon cancer case-
control study nested within the multicenter WHI study.32
The data set contains 483 cases and 530 controls, fre-
quency matched based on age. All participants are female
and self-reported as white. Samples were genotyped with
the Illumina HumanHap550 Genotyping BeadChip.33
Samples with call rate< 98%were excluded; SNP exclusion
criteria was call rate< 98%,MAF< 0.05, or deviations from
Hardy Weinberg equilibrium (p < 0.0001), resulting in
392,361 SNPs. The quantile-quantile plot shows that the
p values for marginal association of log additive model
adjusting for age and the ﬁrst threemajor principal compo-
nents derived by using EIGENSTRAT22 closely follow the
45 line (see Figure S1), with a genomic control value of
1.01. Therefore, we only used the ﬁrst three major prin-
cipal components to account for any potentially hidden
structure in the pathway analysis. SNPs were assigned to
nearby genes by relative distance (see Supplemental Gene
Deﬁnition). Pathways were deﬁned by using the KEGG
database.4 There are a total of 200 KEGG human disease
pathways (details can be found on the KEGG website).
We restricted our analysis to pathways with at least ten
genes, in line with Efron and Tibshirani.13 After exclu-
sions, there are 170 KEGG pathways with 10–253 genes.
The signiﬁcance level 0.05 is used throughout the analysis.The AmeTwo pathways were identiﬁed as signiﬁcant via GRASS
(Table 3). A list of the top ten pathways, all of which
have p < 0.1, is given in Table S1. The highest ranked
pathway is the nicotinate and nicotinamide metabolism
pathway (p¼ 0.015), followed by the transforming growth
factor beta (TGF-beta) signaling pathway (p ¼ 0.035).
Neither is signiﬁcant at level 0.05 after adjusting for mul-
tiple comparison with the Bonferroni correction. Both
pathways have a potential biological role in colon can-
cer etiology. Nicotinamide and nicotinate are the two
main forms of niacin (vitamin B3) and are precursors of
nicotinamide adenine dinucleotide (NAD) and nicotini-
mide phosphate adenine dinucleotide (NADP). NAD and
NADP are cofactor enzymes involved in cellular redox reac-
tions.34 Furthermore, NAD has been shown to play a role
in signaling pathways involved in DNA repair, intracellular
calcium signaling, and transcriptional regulation.34,35
Genes in the nicotinate and nicotinamide metabolism
pathway have been shown to be differentially expressed
in colon cancer cells.34 The TGF-beta signaling pathway
is commonly altered in human cancers.36 The pathway
signals through the TGF-beta serine or threonine kinase
receptors and downstream intercellular proteins of the
SMAD transcription factor family37 to inhibit cell prolifer-
ation and induce apoptosis; the pathway also induces
tumor progression via cell differentiation, migration, and
adhesion.36 See Supplemental Gene Lists for the top two
pathways by GRASS algorithm.
We investigated the sensitivity of the GRASS algorithm
to the choice of convergence criterion and found that the
results of our colon cancer analysis are largely unchanged
with various choices of convergence criterion unless the
estimated penalty parameter, l, changes dramatically
under different criteria. With a relaxed convergence crite-
rion, the l estimates tend to be larger, leading to more
penalization and more conservative p value estimation.
We also applied Wang et al.,7 Plink,18 and ALIGATOR9
pathway methods to the same GWAS data. The Wang
et al. approach identiﬁed a total of 15 signiﬁcant pathways
(see Table S3). None was signiﬁcant after Bonferroni correc-
tion, and the minimum FDR was 0.49. The top pathway is
valine leucine and isoleucine degradation. There is some
observation that the expression of genes in the valine
leucine and isoleucine degradation pathway may be
decreased in metastatic tissue from colon cancer cases.38
For Plink, we chose the default r2 > 0.5 as the SNP LD
ﬁltering criterion and 0.001 as the SNP p value thresh-
old. Eight pathways were found to be signiﬁcant (seerican Journal of Human Genetics 86, 860–871, June 11, 2010 867
Table S3), and none were signiﬁcant after multiple testing
correction. Among the eight pathways, the top one is the
notch signaling pathway, which plays a key role in cell fate
determination. Similar to the TGF-beta pathway, several
genes in this pathway are up- or downregulated in colon
cancer tissue. Interestingly, one mechanism of notch sig-
naling is to inhibit TGF-beta signaling.39,40 We tried two
other thresholds, 0.005 and 0.0001, for p values. A total
of eight and ﬁve pathways, respectively, were identiﬁed.
Among these, ﬁve pathways were identiﬁed by all three
p value thresholds (and they are the top ﬁve pathways).
We also tried another r2 ﬁltering criterion of 0.2. The
results were largely not changed.
When using ALIGATOR to analyze our data, we chose
the same p value threshold, 0.001, as in Plink and found
only one pathway, O-glycan biosynthesis, as signiﬁcant
(see Table S4). The O-linked mucin type glycans are often
altered in colonic disease, including colon cancer. Alter-
ations in O-glycans lead to changes in the interactions
between the intestinal cells and their surrounding
microenvironment. These changes may have oncogenic
effects.41,42 We also used 0.005 and 0.0001 as the thresh-
olds for p values and found four and ﬁve pathways, respec-
tively; none are overlapped.
In terms of computation efﬁciency, ALIGATOR is the
fastest and takes about 1.5 hrs to ﬁnish the analysis of
the WHI data, using 12 computer nodes with 8 processors
each. As a comparison, for the same data set under the
same computing power, the proposed GRASS method
takes ~5 hr and the Wang et al. approach, based on logistic
regression, takes ~24 hr. Plink, as a software, is less
amenable to parallel computing. If it can be parallelized,
the computation time should be similar to GRASS.Discussion
We have developed GRASS, an algorithm that performs
a novel form of regularized logistic regression to assess
the concerted association of genes with disease risk. The
regularization has a dual function: selecting SNPs within
a gene by lasso penalty while simultaneously shrinking
the estimates of the genes by ridge penalty. The method
is most powerful when there are several genes in the
pathway associated with disease risk.
The GRASS algorithm tests the null hypothesis that
none of the genes in a gene set harbor SNPs associated
with disease risk. To test this hypothesis, we estimated
the null statistics from permuting phenotype labeling.
A related null hypothesis12 is that a gene set is not more
enriched with disease-associated genes than a randomly
sampled set of genes. To test the latter hypothesis of
enrichment, one can adapt the resampling procedure to
randomly sampling genes from the genome. In gene
expression data analysis, there are some potential differ-
ences between testing the two hypotheses.12 This is
because many genes are differentially expressed and868 The American Journal of Human Genetics 86, 860–871, June 11,gene-gene correlations are relatively common in expres-
sion data. When testing the latter hypothesis of enrich-
ment by resampling genes, there is also a concern about in-
ﬂated type I error rate12,15 if gene-gene correlation is not
adequately taken into account. Unlike expression data,
GWAS signals are much more sparse, and intergene
correlations are rarely observed. The weak gene-gene corre-
lation is because long-range intergene LD is relatively
uncommon. In our study of GWAS data, we found that
the difference between testing the two hypotheses is rela-
tively small.
In testing either hypothesis, it is important to adjust for
gene size. Because of multiple comparisons, a larger gene is
more likely to produce signiﬁcant associated SNPs than
a smaller gene. If gene size is not properly adjusted, a
bias is likely to occur, and p values of gene set statistics
may be correlated with gene sizes.7 In our algorithm for
gene set association, we permuted phenotypes and stan-
dardized the statistic contributed by each gene while
testing the signiﬁcance of pathways with the same permu-
tation data sets. Interestingly, even after adjustment of
gene size, we found a modest correlation (Pearson correla-
tion¼ 0.191) between our estimated pathway p values and
the number of eigenSNPs in a pathway. This nonzero corre-
lation suggests that there might be more causal variants in
larger pathways with longer genes. In the resampling gene
procedure for testing enrichment, we can additionally
permute the phenotype to standardize the test statistic to
adjust for gene size. However, this is rather costly in
computation time. Alternatively, a weight function may
be imposed in the regularize regression in Equation 2 so
that longer genes are subject to a larger penalty term;
however, the choice of the weight function may become
ad hoc.
Notably, the GRASS algorithm can be applied regardless
of how one groups SNPs to genes. To group SNPs to genes,
one can use absolute genetic distance (e.g., SNPs within
50 kb of the exons of a gene are allocated to the gene7)
or relative distance that allocates each SNP to the nearest
gene. We chose the latter, because it is more comprehen-
sive and ﬂexible. Although grouping by relative distance
could result in misclassiﬁcation and/or false enrichment
with similar SNP representation for nearby genes, this is
less of a concern when considering functional gene sets,
because nearby genes do not often belong to the same
functional set. The GRASS algorithm can also be applied
regardless of how a gene set is deﬁned, for example,
whether the deﬁnition is based on other informatics data-
bases (e.g., GO, MsigDB) or gene networks constructed
from other biologic information (e.g., gene-expression or
protein-protein-interaction networks).
Several approaches have recently been proposed for
pathway analysis that use GWAS data. We compared our
GRASS algorithm with three of them:Wang et al.,7 Plink,18
and ALIGATOR.9 Through simulations, we showed that
our GRASS method generally has good power compared
to other approaches, even when the signal-to-noise ratio2010
is low or when signals reside in smaller genes with modest
LD. In the real data analysis, we can see that different
methods identiﬁed different pathways. This ﬁnding is
not unexpected, because different methods are powerful in
detecting different types of pathways. Ideally, there would
be a benchmark data set with known pathway effects to
compare all of these methods. However, to the best of
our knowledge, such a data set is currently not available.
Alternatively, one can validate these ﬁndings in an inde-
pendent data set, which also may need to be developed.
Wang et al. uses a weighted Kolmogorov-Smirnov test to
assess whether the distribution of the ranks of genes from
the pathway differs from the rest of the genes. Thus,
a signiﬁcant pathway may not necessarily indicate that
the pathway is associated with disease risk. In addition,
Wang et al.’s choice of weight may favor pathways in
which one or a few SNPs have very large test statistics.
Other than choosing the weight, theWang et al. approach,
in fact, does not need any other choices to perform the test.
Both Plink and ALIGATOR, on the other hand, require
that one preselect associated SNPs by using a threshold.
Plink simply averages the test statistics of SNPs that exceed
the threshold, whereas ALIGATOR counts the number of
genes that contain such SNPs. As expected, both methods
can be sensitive to the choice of the threshold. An advan-
tage of ALIGATOR is that it only needs p values or sum-
mary statistics from tests of SNP associations and thus is
particularly useful when individual-level SNP data are not
available, for example, in a large-scale meta analysis.
However, because it does not take into account the sample
variation as in other approaches, the test can be sensitive
to the SNP signiﬁcance threshold if the sample size is small
to moderate, as in the case of WHI data. Plink is quite
powerful if signals reside in genes with dense SNPs.
When the signal-to-noise ratio decreases, the power also
does not reduce as much as the Wang et al. approach or
ALIGATOR, particularly for large genes. This is probably
because Plink makes use of the small to moderate LDs
that are often present in large genes. The GRASS algorithm,
which does SNP selection within genes, appears to be the
least affected when the signal-to-noise ratio is reduced.
We applied the GRASS algorithm to a colon cancer
GWAS data set, using our GRASS algorithm to identify
disease risk-associated gene sets deﬁned by KEGG path-
ways. Although none of the pathways were signiﬁcant
after adjustment for multiple testing, the top pathways
have putative functional connection to colon cancer.
In particular, the second ranked pathway, the TGF-beta
signaling pathway, involves signal transduction and regu-
lation of cell proliferation. Based on our gene deﬁnition,
the TGF-beta pathway includes three chromosomal
regions previously identiﬁed in GWAS studies as being
associated with risk of colorectal cancer: SMAD7
(rs4939827),43 8q24/MYC (rs6983267),44–46 and BMP4
(rs4444253).47 In fact, the TGF-beta pathway was recently
implicated in colorectal cancer based on the ten common
genetic variants identiﬁed from previous GWAS.48The AmeIt is clear that ﬁndings that use the GRASS algorithm or
other approaches need to be replicated in an independent
data set via exactly the same approach as performed in
the original data set. Alternatively, replication could be
done via targeted genotyping, in which speciﬁc SNPs are
selected to validate the pathway ﬁndings. For example,
we can select SNPs that are most correlated with the
eigenSNPs that have nonzero effects in the test statistic
of an identiﬁed pathway. Another way to select SNPs for
replication is that we can ﬁrst detect signiﬁcant genes
within an identiﬁed pathway by comparing the gene statis-
tics in Equation 4 with the null statistics obtained from
the same permutation as in the gene set association anal-
ysis. Then we can choose the most signiﬁcant and nonre-
dundant SNPs in these signiﬁcant genes for replication.
Taking our WHI study as an example, there are ten genes
that are signiﬁcant at level 0.1 in the TGF-beta signaling
pathway. To replicate this ﬁnding in an independent repli-
cation study, we suggest to choose themost signiﬁcant and
nonredundant SNPs, e.g., r2% 0.8, per signiﬁcant gene.
The statistical framework presented by GRASS is general
and ﬂexible. Because it is regression based, it can easily
accommodate other covariates such as age, gender, and
center, as well asmajor principal components,22 to account
for population substructure. It can also be extended to other
high-dimensional settings, when the number of predictors
is large and a priori information is available, to allow the
grouping of predictors. Both the direction of effects in
pathways and the relationship among the genes within a
pathwaymay be incorporated in studying gene-gene inter-
actions. Another extension may include the joint analysis
of multiple related pathways. Given that signals are usually
sparse in GWAS, such joint analysis could be powerful and
illuminating. Research in pathway analysis is rapidly
evolving, andmanymethods have been proposed to assess
the association to disease risk of potential factors based on
gene sets. We believe that with the fast-growing number
of available GWAS data, gene-set-based methods will soon
be more fully utilized for identifying pathways associated
with disease risk. Identiﬁcation of such pathways could
potentially improveourbiological understandingofdisease
processes and help inform clinical decisions for disease
prevention and treatment.Appendix A
Algorithm A1. A Block Coordinate Descent
Algorithm for Minimizing SlðbÞ
Initialize b to be a zero vector
repeat
b0)arg minb0SlðbÞ
for each gene g ¼ 1, ., G do
ﬁnd the optimal bg while ﬁxing other bg 0 ðg 0sgÞ,
bg)arg minbg SlðbÞ
end for
until some convergence criterion is metrican Journal of Human Genetics 86, 860–871, June 11, 2010 869
Algorithm A2. GRASS
for any given candidate gene set S do
for each gene g ¼ 1, ., G do
apply PCA on the standardized SNP matrix and
obtain the n 3 kg eigenSNP matrix Vg that represents
most, if not all, of the genetic variation in the gene
end for
X) V1,.,VGgf
apply group ridge logistic regression on the eigenSNP
matrix X and the phenotype y (Algorithm A1), choose
l by using AIC, and obtain the regularized b estimates
for b ¼ 1,., B do
permute phenotype y and obtain yb, apply Algorithm
A1 with the same l chosen using the original data set,
and obtain the estimates b0 under the null
end for
for g ¼ 1,., G do
calculate themean and the standard deviation of kbgk
under the null, as deﬁned in Equation 3, from b0g
standardize the observed and the null gene estimates
by Equation 4
end for
compute the observed and null association statistics, Tl
and T0b(l), b ¼ 1,., B, for the gene set S by Equation 5
calculate p value by comparing the observed gene set
association statistic with the null statistics by Equation 6
end for
Supplemental Data
Supplemental Data include Supplemental Experimental Proce-
dures, two algorithms, four tables, and one ﬁgure and can be
found with this article online at http://www.ajhg.org.
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